NCT02704767

Tarceva With or Without Apatinib in the Advanced Lung Adenocarcinoma

Tarceva With or Without Apatinib in the First-line Therapy of Advanced Lung Adenocarcinoma With Mutant EGFR:a Phase II Study.

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: First Affiliated Hospital of Kunming Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Tarceva now was established first-line therapy for advanced lung adenocarcinoma with mutant EGFR patients.However,the benefit lasted for about 6-8 months.So we consider to add apatinib,a tyrosine kinase inhibitor of VEGF,to the therapy of these patients.

Detailed description

Lung adenocarcinoma is the most common NSCLC,most patient were diagnosed to advanced stage.The first-line therapy include chemotherapy of targeted therapy .Tarceva now was established first-line therapy for advanced lung adenocarcinoma with mutant EGFR patients.However,the benefit lasted for about 6-8 months.So we consider to add apatinib,a tyrosine kinase inhibitor of VEGF,to the therapy of these patients.We designed the study to find out whether the addition of apatinib to the Tarceva would enhance the efficacy of Tarceva.

Conditions

• Lung Cancer

Interventions

Type	Name	Description
DRUG	Apatinib	a tyrosine kinase inhibitor of VEGF invented by Hengrui pharma in China
DRUG	Tarceva
DRUG	Placebo

Timeline

• Start date: 2016-06-01
• Primary completion: 2019-06-01
• Completion: 2019-12-01
• First posted: 2016-03-10
• Last updated: 2016-03-10